18:31:11 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-02-19 Bokslutskommuniké 2024
2024-11-13 Kvartalsrapport 2024-Q3
2024-08-20 Kvartalsrapport 2024-Q2
2024-05-21 Ordinarie utdelning BICO 0.00 SEK
2024-05-20 Årsstämma 2024
2024-05-07 Kvartalsrapport 2024-Q1
2024-02-20 Bokslutskommuniké 2023
2023-11-14 Kvartalsrapport 2023-Q3
2023-08-22 Kvartalsrapport 2023-Q2
2023-05-10 Ordinarie utdelning BICO 0.00 SEK
2023-05-09 Årsstämma 2023
2023-05-04 Kvartalsrapport 2023-Q1
2023-02-22 Bokslutskommuniké 2022
2022-12-14 Extra Bolagsstämma 2022
2022-11-09 Kvartalsrapport 2022-Q3
2022-08-24 Kvartalsrapport 2022-Q2
2022-05-18 Kvartalsrapport 2022-Q1
2022-04-27 Ordinarie utdelning BICO 0.00 SEK
2022-04-26 Årsstämma 2022
2022-02-23 Bokslutskommuniké 2021
2021-11-17 Extra Bolagsstämma 2021
2021-11-10 Kvartalsrapport 2021-Q3
2021-08-18 Kvartalsrapport 2021-Q2
2021-05-12 Kvartalsrapport 2021-Q1
2021-04-27 Ordinarie utdelning BICO 0.00 SEK
2021-04-26 Årsstämma 2021
2021-02-25 Bokslutskommuniké 2020
2020-12-18 Ordinarie utdelning BICO 0.00 SEK
2020-12-17 Extra Bolagsstämma 2020
2020-10-22 Kvartalsrapport 2020-Q3
2020-04-09 Kvartalsrapport 2020-Q2
2020-01-20 Kvartalsrapport 2020-Q1
2020-01-10 Split BICO 1:4
2019-12-19 Ordinarie utdelning BICO 0.00 SEK
2019-12-18 Årsstämma 2020
2019-10-24 Bokslutskommuniké 2019
2019-08-26 Extra Bolagsstämma 2019
2019-07-11 Kvartalsrapport 2019-Q3
2019-04-10 Kvartalsrapport 2019-Q2
2018-12-14 Ordinarie utdelning BICO 0.00 SEK
2018-12-13 Årsstämma 2019
2018-10-24 Bokslutskommuniké 2018
2018-07-11 Kvartalsrapport 2018-Q3
2018-04-11 Kvartalsrapport 2018-Q2
2018-01-17 Kvartalsrapport 2018-Q1
2017-12-15 Ordinarie utdelning BICO 0.00 SEK

Beskrivning

LandSverige
ListaMid Cap Stockholm
SektorHälsovård
IndustriMedicinteknik
BICO Group är verksamma inom medicinteknik. Bolaget är specialiserade inom biokonvergens och tillhandahåller teknik, produkter och tjänster för biologi. Med fokus på applikationsområdena bioprintning, multiomics, cellinjeutveckling och diagnostik utvecklar och marknadsför bolaget teknik som gör det möjligt för forskare att odla celler i 3D-miljöer, genomföra läkemedelsscreening och skriva ut mänskliga vävnader och organ för medicinsk, läkemedels- och kosmetisk industri.
2024-03-15 07:15:00

Following discussions with the board, the company's founders Erik Gatenholm and Hector Martinez are leaving BICO after eight years. "I want to thank Erik and Hector for their efforts. Without them, the company would not have existed, let alone contributed to the change in the industry," says Rolf Classon, Chairman of the Board. "I wish them both the best of luck in the future.”

Erik Gatenholm and Hector Martinez, together with one other person, founded the company in 2016. Until November 20, 2023, Erik Gatenholm was also President and CEO of the company.

Since then, he has held a role as a senior advisor and remained a member of the Board of Directors. Hector Martinez was on the board until 2019 and has been CTO and since January 2022 Deputy CEO of the company until today. Today's announcement means that Erik Gatenholm has today left the role of senior advisor and that Hector Martinez has terminated his position as CTO and Deputy CEO. Erik Gatenholm also announces that he will not stand for re-election to the board.

Rolf Classon states that several things have contributed to the discussion, including the recently presented external whistleblower investigation where the company's aggressive sales culture during the years 2017-2021 was highlighted. The report has not been able to show that any crime has occurred and does not lead to any further accounting measures, but the board and the founders take the matter very seriously.

Some of the issues raised by the external investigation were already revealed in 2022 by the internal investigation conducted at that time. The company therefore made write-downs of account receivables and then continued the work that had previously been initiated to strengthen the internal control systems. 

Rolf Classon emphasizes that the discussion is also about market confidence.
All founders have an impact on the company's culture. Therefore, as a result of what has been happening, it is natural that Erik Gatenholm and Hector Martinez, who were both founders and CEO and CTO and Deputy CEO respectively, have now left out of concern for the company," says Rolf Classon.

Erik Gatenholm will leave the board at the general meeting on May 20, 2024. In connection with the notice of the general meeting, the Nomination committee's proposal for the board will be presented.